The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Open accessAbstract
BACKGROUND: p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response, disease control (defined as complete response, partial response, or stable disease), progression-free survival, overall survival, and safety. Exploratory biomarkers were evaluated for their association with response to sotorasib therapy. RESULTS: . CONCLUSIONS: p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sotorasib response rate in colorectal cancer is lower than that in NSCLC (7).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, in a preliminary analysis, the response rate of MRTX849 in NSCLC patients harboring mutations in both KRAS G12C and KEAP1 was reduced compared to the response rate in KRAS G12C , KEAP1 WT patients [13, 14].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, KRAS G12C inhibition produces substantially different outcomes in NSCLC and CRC, largely due to lineage-specific feedback regulation [23,26,27,28,32].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sotorasib and adagrasib, two prominent members of this class, were effective at halting the growth of G12C-mutant cancer cells in 2-dimensional, 3-dimensional, and xenograft models, clearing the path for clinical trials [48,49,50,51].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [49]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but all patients eventually developed therapeutic resistance, limiting long-term survival.19”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have revealed that sotorasib demonstrates satisfactory efficacy in patients with non–small cell lung cancer, with a satisfactory response rate [12, 13].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, patients with KRASG12C-mutated non–small cell lung cancer achieved a durable clinical benefit from sotorasib, the first approved KRASG12C mutant-selective inhibitor, whereas patients with CRC bearing the same mutation responded less to the same treatment [12].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotorasib was associated with an objective response rate of 37.1% and a median progression-free survival of 6.8 months among patients with NSCLC14 and a response rate of 7.1% among those with colorectal cancer.10”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, AMG510 treatment in patients with KRASG12C-driven NSCLC achieved a response rate of over 30%,18,19”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“For sotorasib, an overall response rate (ORR) of 7.1–9.7% was observed in patients with advanced CRC, compared to 32.2–37.1% in those with advanced NSCLC (Table 1) [26, 46, 47].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, sotorasib has been shown to strongly inhibit phosphorylation of ERK protein in KRASG12C cells, thereby suppressing cell proliferation.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“Sotorasib specifically and irreversibly inhibits KRASG12C by binding to GDP and locking KRAS in an inactive state.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“The approval of Lumakras, an Amgen-developed drug, in May 2021 for treating NSCLC patients with KRASG12C mutations marks a significant milestone in KRAS-targeting drug discovery.53”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“Some preclinical and clinical studies have reported that some drugs could reverse resistance induced by RAS, such as sotorasib, dasatinib and metformin [155,156,157].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [157]
In the citing paper
“In terms of gastrointestinal adverse effects frequently observed in other KRAS G12C inhibitors, 11,12,28 the incidence was generally lower in garsorasib (diarrhea at 11.5%, nausea at 7.7%, and no vomiting reported), compared to those reported of other KRAS G12C inhibitors (diarrhea at 31.7-69%, nausea at 19-78%, and vomiting at 7.9-58%).”
In the citing paper
“Both also showed antitumor activity against KRASG12C-mutated tumors in early-phase clinical trials (20), leading to the accelerated approval of sotorasib by the FDA in May 2021 and conditional marketing authorization by the European Commission in January 2022.”
In the citing paper
“Single-agent JDQ443 demonstrated antitumor activity in both panels, with deeper responses in NSCLC than colorectal cancer (Fig. 4A vs. 4E; Supplementary Table S7), consistent with reported clinical findings for other single-agent KRASG12C inhibitors in these indications (20, 21, 25, 33).”
In the citing paper
“Some of these inhibitors have proven efficacy in patients with KRASG12C-mutant cancers and have become practice changing.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“The phase II portion of CodeBreaK 100, which involved 124 evaluable patients with previously treated advanced-stage KRASG12C-mutant NSCLC, demonstrated an ORR of 37.1%, a median duration of response (DoR) of 11.1 months, median PFS of 6.8 months and median OS of 12.5 months67. These impressive results led to the 2021 FDA accelerated approval of sotorasib for this indication.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“However, the data on KRASG12C inhibitors, which have advanced the furthest in development and are entering clinical practice, emphasize that these agents are far from curative67.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [7]
In the citing paper
“Preclinical and clinical studies, however, have demonstrated that cancers lose sensitivity to KRASG12Ci and re-establish RAS-MAPK signaling through multiple mechanisms, including increased activation of mutant or wild-type (WT) RAS and/or gain of upstream/downstream bypass events1,7,9,10,13,14.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [7]
In the citing paper
“sotorasib (AMG 510) and adagrasib (MRTX849) have demonstrated robust efficacy with objective response rates of 37% and 45%, and disease control rates of 81% and 96%, respectively (20, 23–25).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“Exploratory correlative analyses from the KRYSTAL-1 and CodeBreaK 100 trials in this context suggest higher response rates for single agent adagrasib (64% vs 45%) and sotorasib (50% vs 39%) among patients whose tumors harbored an STK11 co-mutation, versus the entire treatment cohort (24, 25).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“While KRASG12C inhibitors deliver clinical benefit, all patients who achieved an objective response ultimately progressed on treatment with sotorasib in a Phase II study (24).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“In the updated analysis, the overall response rate remained at 37.1% although one of the partial responses converted to a complete response.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The updated analysis provided the first report of overall survival for NSCLC patients treated with a selective KRAS G12C inhibitor.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Per recent subgroup analyses of the Phase II NSCLC cohort from CodeBreaK 100, patients appear to derive benefit after PD1/PD-L1 checkpoint inhibition, including the application of the checkpoint inhibitor within 3 months of sotorasib initiation31.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Patients whom have had checkpoint therapy within 3 months had overall response of 34.4% and median overall survival of 11.7 months, compared to 39.7% and not evaluable in patients that had more than 3 months between checkpoint inhibition and sotorasib.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“These data may indicate that prior immune therapy does not meaningfully negatively impact the activity of sotorasib, suggesting a possible combination approach may be further explored given non-overlapping mechanisms of action.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Recent overall survival data has been favorable with an overall survival of 12.5 months including second and third line and beyond patients receiving benefit.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [12]
In the citing paper
“Median PFS was 6.8 months and median survival was 12.5 months (Table 2).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“The NSCLC cohort included 126 patients, 81% of whom had received prior platinum-based chemotherapy and PD(L)1 inhibitor therapy. With a median follow-up of 15.3 months, the response rate was 37.1%; 80.6% of patients achieved disease control.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“While ORR was 50% in those with mutated STK11 and wild-type KEAP1, it was only 23% when both KEAP1 and STK11 were mutated and 14% when KEAP1 was mutated with wild-type STK11 (Table 3).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“Nevertheless, drugs again other KRAS mutations in codons 12, 13 and 61 still remain to be developed [87].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [87]
In the citing paper
“Sotorasib (AMG-510) (Table 1) was the first selective KRAS(G12C) inhibitor to enter clinical trials in 2018 and was developed by Amgen, building on discoveries from a partnership with Carmot Therapeutics in which a custom library of small molecules that covalently bind cysteine were screened against KRAS(G12C)93.”
From Advances in covalent drug discovery (2022) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,004
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Bironzo, P., Cani, M., Jacobs, F., Napoli, V. M., Listì, A., Passiglia, F., Righi, L., Maïo, M. D., Novello, S., & Scagliotti, G. V. (2023) · Cancer · doi:10.1002/cncr.34731 · Cited by 14
Chen, T., Tang, X., Tang, X., Feng, F., Xu, C., Zhao, Q., Wu, Y., Sun, H., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115828 · Cited by 14
Finally, Effective Inhibitors of Mutant KRAS
Rosen, N. X. (2021) · New England Journal of Medicine · doi:10.1056/nejme2107884 · Cited by 14
Targeting Oncogenic RAS Protein
Longo, D. L., & Rosen, N. X. (2022) · New England Journal of Medicine · doi:10.1056/nejme2206831 · Cited by 15
KRAS inhibitors: going noncovalent
Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13341 · Cited by 13
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13
Self-citationGrosjean, H., Aimon, A., Hassell‐Hart, S., Thompson, W. A., Koekemoer, L., Bennett, J. M., Bradley, A. R., Anderson, C., Wild, C. F., Bradshaw, W. J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202424373 · Cited by 13
RAS Pathway Mutations and Therapeutics in Vascular Anomalies
Alharbi, S., Merkle, S., Hammill, A. M., Waters, A. M., & Cras, T. D. L. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31605 · Cited by 14
Álvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., Arenas, A. M., Hernández-Navas, I., Benitez‐Cantos, M. S., Andrades, Á., Fariñas, S. C., Lewintre, E. J., Paz-Ares, L. G., Ferrer, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62350-4 · Cited by 15
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 15
Burns, T. F., Ammakkanavar, N. R., Hollebecque, A., Lee, D. H., Koyama, T., Cassier, P. A., Italiano, A., Han, J., Singhal, N., Takeuchi, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.018 · Cited by 14
Self-citationLung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Sun, T. Y., Hendifar, A. E., & Padda, S. K. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01253-9 · Cited by 13
Guo, M. Z., Murray, J. C., Ghanem, P., Voong, K. R., Hales, R. K., Ettinger, D. S., Lam, V. K. L., Hann, C. L., Forde, P. M., Brahmer, J. R., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.002 · Cited by 12
Nath, R., Singha, S., Nath, D., Das, G., Patra, J. K., & Talukdar, A. D. (2022) · Applied Sciences · doi:10.3390/app122211749 · Cited by 15
Top advances of the year: Precision oncology
Desai, A. P., Reddy, N. K., & Subbiah, V. (2023) · Cancer · doi:10.1002/cncr.34743 · Cited by 14
Haynes, D., Morgan, E. E., & Chu, E. Y. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.04.014 · Cited by 14
Zhang, R., Shi, K., Hohenforst‐Schmidt, W., Steppert, C., Sziklavári, Z., Schmidkonz, C., Atzinger, A., Hartmann, A., Vieth, M. W., & Förster, S. (2023) · Cancers · doi:10.3390/cancers15143684 · Cited by 14
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
Meira, D. D., Caetano, M. C. D. C. E., Casotti, M. C., Zetum, A. S. S., Gonçalves, A. F. M., Moreira, A. R., de Oliveira, A. H., Pesente, F., Santana, G. M., Duque, D. D. A., et al. (2023) · Genes · doi:10.3390/genes14101906 · Cited by 14
Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 14
RAS/RAF landscape in monoclonal plasma cell conditions
Schavgoulidze, A., Corre, J., Samur, M., Mazzotti, C., Pavageau, L., Perrot, A., Cazaubiel, T., Leleu, X. P., Macro, M., Belhadj, K., et al. (2024) · Blood · doi:10.1182/blood.2023022295 · Cited by 14
Toyoda, T., Miura, N., Kato, S., Masuda, T., Ohashi, R., Matsushita, A., Matsuda, F., Ohtsuki, S., Katakura, A., & Honda, K. (2024) · Cancer Science · doi:10.1111/cas.16302 · Cited by 13
Dowdell, A. K., Meng, R., Vita, A., Bapat, B., Hanes, D. A., Chang, S., Harold, L., Schmidt, M., Wong, C., Poon, H., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00226 · Cited by 13
Liu, Z., Li, Y., Wang, S., Wang, Y., Sui, M., Liu, J., Chen, P., Wang, J., Zhang, Y., Dang, C., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03338-2 · Cited by 13
Ghazali, N., Garassino, M. C., Leighl, N. B., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323985 · Cited by 13
Zieliński, P., Stępień, M., Chowaniec, H., Kalyta, K., Czerniak, J., Borowczyk, M., Dwojak, E., Mroczek, M., Dworacki, G., Ślubowska, A., et al. (2025) · Cells · doi:10.3390/cells14080587 · Cited by 14
Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review
Zaitouni, S. E., Laraqui, A., Boustany, Y., Benmokhtar, S., Annaz, H. E., Abi, R., Tagajdid, M. R., Kochri, S. E., Bouaiti, E. A., Amine, I. L., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251331759 · Cited by 13
Chen, C., Chen, X., Zhang, Y., Zhang, Q., & Shi, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1605085 · Cited by 14
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
Roberts, S. K., Galgadas, I., Clarke, D. T., Zanetti-Domingues, L. C., Gervasio, F. L., & Martin-Fernandez, M. L. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104407 · Cited by 14
Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
Aran, V., Zalis, M. G., Montella, T. C., de Sousa, C. A. M., Ferrari, B. L., & Ferreira, C. G. (2021) · Medicina · doi:10.3390/medicina57101039 · Cited by 14
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
Arbour, K. C., Manchado, E., Bott, M. J., Ahn, L. S. H., Tobi, Y. Y., Ni, A. A., Yu, H. A., Shannon, A., Ladanyi, M., Perron, V., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100256 · Cited by 13
Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
Pîrlog, R., Piton, N., Lamy, A., Guisier, F., Berindan‐Neagoe, I., Sabourin, J., & Marguet, F. (2022) · Cancers · doi:10.3390/cancers14041030 · Cited by 13
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 15
Fu, F., Deng, C., Sun, W., Zheng, Q., Jin, Y., Li, Y., Zhang, Y., & Chen, H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02201-8 · Cited by 17
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 14
Loos, N. H. C., Retmana, I. A., Rijmers, J., Wang, Y., Gan, C., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115304 · Cited by 13
Dahal, U. P., Rock, B. M., Rodgers, J., Shen, X., Wang, Z., & Wahlstrom, J. L. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000798 · Cited by 13
Skoulidis, F., Li, B. T., Hochmair, M. J., Govindan, R., Vincent, M. D., van der Wekken, A. J., Aransay, N. R., O'Byrne, K. J., Girard, N., Griesinger, F., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyae356 · Cited by 13
Self-citation50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Ramalingam, P. S., Chellasamy, G., Hussain, M. S., Muthukaliannan, G. K., Hussain, T., Alrokayan, S., Yun, K., Ramaiah, M. J., & Arumugam, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1635449 · Cited by 12
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C. E., et al. (2025) · Blood · doi:10.1182/blood.2025030558 · Cited by 16
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Wing, S. E., Jankowska, M. M., Zou, X., Sosa, E., Yang, J., Benmarhnia, T., Neuhausen, S. L., Nelson, R., Salgia, R., Gray, S. W., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04455-7 · Cited by 13
Liao, Y., Chan, S. C., Welsh, E. A., Fang, B., Sun, L., Schönbrunn, E., Koomen, J. M., Duckett, D. R., Haura, E. B., Monastyrskyi, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00587 · Cited by 12
Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
Morafraile, E. C., Saiz-Ladera, C., Nieto-Jiménez, C., Győrffy, B., Nagy, A., Velasco, G., Pérez-Segura, P., & Ocaña, A. (2023) · Current Oncology · doi:10.3390/curroncol30030196 · Cited by 12
Herzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 15
Tanaka, I., Koyama, J., Itoigawa, H., Hayai, S., & Morise, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249237 · Cited by 13
Hendry, S. A., Mamotte, L., Ardakani, N. M., Leslie, C., Tesfai, Y., Grieu‐Iacopetta, F., Izaac, K., Singh, S., Ardakani, R. M., Thomas, M. A., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.08.002 · Cited by 12
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 14
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
Sisoudiya, S. D., Houle, A. A., Fernando, T. M., Wilson, T. R., Schutzman, J. L., Lee, J., Schrock, A. B., Sokol, E. S., Sivakumar, S., Shi, Z., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00644-4 · Cited by 13
Ogawa, A., Yoshida, H., Kawano, S., Kikkawa, N., Kato, M. K., Tanase, Y., Uno, M., & Ishikawa, M. (2024) · Current Oncology · doi:10.3390/curroncol31090378 · Cited by 12
Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN )
Doll, J., Maurus, K., Köhler, F., Matthes, N., Lock, J. F., Germer, C., Rosenwald, A., & Wiegering, A. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23270 · Cited by 12
Urtecho, S. B., Provenzano, L., Spagnoletti, A., Bottiglieri, A., Pircher, C. C., Massa, G., Sposetti, C., Proto, C., Brambilla, M., Occhipinti, M. A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108051 · Cited by 12
He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Foffano, L., Bertoli, E., Bortolot, M., Torresan, S., Carlo, E. D., Stanzione, B., Conte, A. D., Puglisi, F., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020583 · Cited by 12
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
Sotorasib effective in KRAS-mutant NSCLC
Sidaway, P. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00533-w · Cited by 12
Serna‐Blasco, R., Sánchez‐Herrero, E., Sanz‐Moreno, S., Rodríguez-Festa, A., García‐Veros, E., Casarrubios, M., Sierra‐Rodero, B., Briviesca, R. L., Cruz‐Bermúdez, A., Mielgo-Rubio, X., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100279 · Cited by 12
Corke, L., & Sacher, A. G. (2021) · Current Oncology · doi:10.3390/curroncol29010004 · Cited by 15
Self-citationCiardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 13
Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review
Samarth, N. H., Gulhane, P., & Singh, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1089320 · Cited by 16
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Moldvay, J., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 15
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
Wu, J., Li, X., Wu, C., Wang, D., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116282 · Cited by 13
Updates on therapy for medullary thyroid cancer in 2021
Puerto, M., Borson‐Chazot, F., & Tabarin, A. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.12.002 · Cited by 12
Wang, J., Lv, X., Huang, W., Quan, Z., Li, G., Wu, S., Wang, Y., Xie, Z., Yan, Y., Li, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.862581 · Cited by 12
Araújo, D. V., Uchoa, B., Castillo, J. J. S., Furlan, L. L., & Oliva, M. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00890-1 · Cited by 12
New Targeted Therapy for Non-Small Cell Lung Cancer
Chung, E., Yong, S. H., Lee, E. H., Kim, E. Y., Chang, Y. S., & Lee, S. H. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0066 · Cited by 14
Sato, K., Akamatsu, H., Koh, Y., Ogawa, K., Isa, S., Ando, M., Tamiya, A., Kubo, A., Kitagawa, C., Kawaguchi, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10246-7 · Cited by 13
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint
Sang, B., Ye, L. F., Hu, F., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Fu, Z. Q., Washington, A., Rodriguez, D. J., Vides, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.649345 · Cited by 12
Self-citationLKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“For instance, STK11 /LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors 9,10 and KRAS G12C inhibitors 3,4 .”
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Emerging insights to lung cancer drug resistance
Su, C. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.61 · Cited by 12
Ito, M., Miyata, Y., Kushitani, K., Ueda, D., Takeshima, Y., & Okada, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-10716-6 · Cited by 11
Zhang, H., Nabel, C. S., Li, D., O’Connor, R. Í., Crosby, C. R., Chang, S. M., Yuan, H., Stanley, R., Sahu, S., Levin, D. S., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.014 · Cited by 11
Yang, C., Shih, J., Liao, W., Ho, C., Hsu, C., Tsai, T.-H., Wu, S., Lin, Y., Hsu, W., Jain, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113310 · Cited by 11
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect
Caggiano, E. G., & Taniguchi, C. M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10157-4 · Cited by 13
Kumar, V., Yochum, Z. A., Devadassan, P., Huang, E. H. ‐., Miller, E., Baruwal, R., Rumde, P. H., Gaither‐Davis, A., Stabile, L. P., & Burns, T. F. (2024) · Oncogene · doi:10.1038/s41388-024-02987-5 · Cited by 11
Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications
Rekha, T. N., & Mohammed, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116441 · Cited by 11
Ding, K., Peng, Z., & Xu, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241249041 · Cited by 12
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Principe, D. R., Pasquinelli, M. M., Nguyen, R. H.-T., Munshi, H. G., Hulbert, A., Aissa, A. F., & Weinberg, F. D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0153 · Cited by 12
Zhou, Q. H., Yang, N., Zhao, M., Huang, D., Zhao, J., Yu, Y., Yuan, Y., Sun, L., Dong, X., Zhang, T., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114337 · Cited by 11
Cina, C., Majeti, B. K., O’Brien, Z., Wang, L., Clamme, J., Adami, R. C., Tsang, K. Y., Harborth, J., Ying, W., & Zabludoff, S. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0915 · Cited by 15
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review
Podder, V., Ranjan, T., Gowda, M., Camacho, A. M., & Ahluwalia, M. S. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01388-1 · Cited by 12
Shin, H. Y., Hwang, S., Jeong, J. H., Shin, S. C., Oh, Y., Kim, J. H., Hwang, I., Kim, E. E., Choo, H., & Song, E. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107722 · Cited by 11
Network-Based Approaches for Drug Target Identification
Koutsandreas, T., Tsafou, K., Horn, H., Barrett, I. P., & Petsalaki, E. (2025) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-101424-120950 · Cited by 14
Lloyd, M. R., Chica-Parrado, M. D. R., Weipert, C. M., Knepper, T. C., Podany, E. L., Napolitano, F., Ye, D., Lin, C.-C. A., Uemoto, Y., Liao, J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105828 · Cited by 11
Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop
Glasmacher, A. G., Garralda, E., Gwaltney, C. J., Rupalla, K., Li, C., & Weber, H. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115593 · Cited by 11
Optimising Outcomes in Non Small Cell Lung Cancer: Targeting Cancer Cachexia
Phillips, I., Stares, M. D., Allan, L., Sayers, J., Skipworth, R. J. E., & Laird, B. J. A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704129 · Cited by 11
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
Pisapia, P., Iaccarino, A., Luca, C. D., Acanfora, G., Bellevicine, C., Bianco, R., Daniele, B., Ciampi, L., Felice, M. D., Fabozzi, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158541 · Cited by 11
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer
D’Aiello, A., Miao, E., & Cheng, H. (2023) · Cancers · doi:10.3390/cancers15030844 · Cited by 13
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Sisler, D. J., Hinz, T. K., Le, A. T., Kleczko, E. K., Nemenoff, R. A., & Heasley, L. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094123 · Cited by 11
Check, J. H., Poretta, T., CHECK, D. L., & Srivastava, M. D. (2023) · Anticancer Research · doi:10.21873/anticanres.16240 · Cited by 11
New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA)
Becht, R., & Wasilewicz, M. P. (2023) · Medicina · doi:10.3390/medicina59061174 · Cited by 11
Durojaye, O. A., Ejaz, U., Uzoeto, H. O., Fadahunsi, A. A., Opabunmi, A. O., Ekpo, D. E., Sedzro, D. M., & Idris, M. O. (2023) · Amino Acids · doi:10.1007/s00726-023-03304-2 · Cited by 11
Green, T. E., MacGregor, D. P., Carden, S. M., Harris, R. V., Hewitt, C., Berkovic, S. F., Penington, A., Scheffer, I. E., & Hildebrand, M. S. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006133 · Cited by 11
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?
Popat, S., & Ratain, M. J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115044 · Cited by 11
Kwon, J. J., Dilly, J., Liu, S., Kim, E., Bian, Y., Dharmaiah, S., Tran, T. H., Kapner, K. S., Ly, S. H., Yang, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.618529 · Cited by 13
Vidimar, V., Park, M., Stubbs, C. K., Ingram, N. K., Qiang, W., Zhang, S., Gursel, D., Melnyk, R. A., & Satchell, K. J. F. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0550 · Cited by 10
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein
Janssen, K., Claes, F., Van de Velde, D., Wehbi, V. L., Houben, B., Lampi, Y., Nys, M., Khodaparast, L., Khodaparast, L., Louros, N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214921120 · Cited by 10
Metadata
- Authors
- Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., Kato, T., Curioni-Fontecedro, A., Sacher, A., Spira, A., Ramalingam, S. S., Takahashi, T., Besse, B., Anderson, A., Ang, A., Tran, Q., Mather, O., Henary, H., Ngarmchamnanrith, G., Friberg, G., Velcheti, V., & Govindan, R.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (F.S.), and U.S. Oncology Research, the Woodlands (A. Spira) — both in Texas; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (B.T.L.) and Thoracic Medical Oncology, Perlmutter Cancer Center, New York University (V.V.), New York, and Roswell Park Cancer Institute, Buffalo (G.K.D.) — all in New York; the Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia (T.J.P.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), the West German Cancer Center, University Hospital Essen, University Duisburg–Essen, Essen (M.S.), and the German Cancer Consortium, Heidelberg (M.S.) — all in Germany; the Early Phase Trials and Sarcoma Units, Bergonie Cancer Institute, Bordeaux (A.I.), and Gustave Roussy Institute, Villejuif (F.B., B.B.) — both in France; Fox Chase Cancer Center, Philadelphia (H.B....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-24
- Volume
- 384
- Issue
- 25
- Pages
- 2371-2381
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9116274
- OpenAlex
- W3172081492
- Semantic Scholar
- 3c89f24ad219bec52684f03b8df3c5d8feb81a72
- Cited by
- 1,849
- References
- 39
- Citations by year
- 2026: 317 · 2025: 348 · 2024: 398 · 2023: 382 · 2022: 319 · 2021: 84
- FWCI
- 192.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, non-small cell lung cancer, KRAS inhibitors, advanced solid tumors, objective response, progression-free survival, biomarkers, drug safety
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Pyridines, Pyrimidines, Biomarkers, Proto-Oncogene Proteins p21(ras), B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
